Sponsored by
This applies to England and Wales. NICE is the "National Institute for Health and Care Excellence" that determines what care you can get in those countries. The new guidelines are a good start, but do not go nearly far enough. They do say adults with high grade gliomas should get Gleolan to improve the chances of a total resection. That alone can bump up the survival rate. However, they dropped the ball by not saying all needed treatments should be covered. For example, Optune is not available in England yet. And Optune had the best result of any reported phase 3 trial for Glioblastoma. Our biggest challenge in the USA is getting coverage for off label drugs and access to experimental drugs. NICE could have taken a stand to speeding up the search for the cure by allowing these in England but they did not.